ClinicalTrials.gg
CompletedNCT01397799Updated Dec 7, 2015

Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

A Phase 1 interventional study of KX2-391 in Acute Myelogenous Leukemia, sponsored by Kinex Pharmaceuticals Inc.. Completed at 3 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2015-12-07.

Sponsored by Kinex Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
1,190th of 1,907
24 · median 35
Started
2013
with 96 others
Phase 1
772 of 2,137
130 open now
Registered
830th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,190th largest by enrollment of the 1,907 interventional ones that give a count, is one of 97 that started in 2013, is one of 772 in phase 1, and was the 830th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This Phase 1b study will determine the maximum tolerated dose of KX2-391 given as a once-daily dose, in elderly patients with acute myelogenous leukemia.

Read the detailed description

KX2-391 has been evaluated in a Phase 1 dose escalation study in patients with solid tumors using twice-daily dosing. This study will employ the Storer's two-stage design to determine the maximum tolerated dose of KX2-391 mono-therapy,given as a once-daily oral dose,in elderly patients with acute myelogenous leukemia (AML) who are refractory to or have declined standard induction therapy. The safety, tolerability, pharmacokinetics and activity of KX2-391 will be evaluated.

03

Conditions studied

  • Acute Myelogenous Leukemia

Keywords

  • Acute Myelogenous Leukemia
  • AML
  • Refractory
  • Elderly
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written .
  • Either de novo or secondary AML by 2008 World Health Organization (WHO) classification.
  • A bone marrow and aspirate sample must be obtained between Day -14 to Day -1, and this sample must be confirmed to be adequate for morphologic analysis of marrow cellularity and blast percentage before the first dose of KX2-391 is administered.
  • A bone aspirate sample (with or without biopsy) must be obtained after the patient signs the informed consent document and be submitted for baseline pharmacodynamic assessment. Although this will usually be obtained as part of the baseline assessment marrow biopsy and aspirate procedure described above, if a complete marrow evaluation was performed prior to the patient signing informed consent, a dedicated bone marrow aspiration for this sample can be performed after the patient signs informed consent, so long as the pre-consent biopsy and aspirate procedure were done within 14 days of the first dose of KX2-391.
  • Adults age ≥ 60 years of age
  • (ECOG) performance status ≤ 2
  • of at least 6 weeks from first day of study drug administration
  • Adequate liver function (/ALT \< 3 x (ULN), Alk Phos \< 2.5 x ULN, and Direct \< 1.5 x ULN)
  • Adequate renal function (serum creatinine \< 1.5 x ULN)
  • Documented ≤ 0.48 seconds within 14 days of first dose of KX2-391

Exclusion criteria

Exclusion Criteria:

  • Subjects with acute promyelocytic leukemia (APL, AML FAB type M3), or chronic myelogenous leukemia (CML).
  • Have not resolved toxicity from previous anticancer treatments or agents, other than hematologic toxicities or alopecia, to ≤ Grade 1 according to the most recent guidelines.
  • Subjects with rapidly proliferative AML that is likely to require treatment within the next 30 days (e.g. hydroxyurea).
  • Received an investigational agent within 5 half-lives of that agent from the anticipated Cycle 1 Day 1 of treatment with KX2-391.
  • Have clinical evidence of central nervous system involvement by AML or other .
  • History of major surgery to the upper gastrointestinal tract, or have a history of inflammatory bowel disease, malabsorption syndrome, or other medical condition that may interfere with oral drug absorption.
  • Uncontrolled hypertension (at time of dosing).
  • Other medical conditions which, in the opinion of the investigator, make it undesirable for the subject to participate in the study.
  • Known history of , C, or human immunodeficiency () infection.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection. Patients receiving intravenous antibiotics for infections that are under control may be included in this study.
  • Subjects who are unwilling or unable to comply with the protocol.
  • Subjects who are taking moderate or strong CYP450 3A4 modulators, with the exception of fluconazole (see Appendix 2 for list of medications currently known to be moderate or strong CYP450 3A4 modulators). Subjects who can safely discontinue these medications can become eligible for this trial.
  • Subjects receiving azole-based antifungal prophylaxis other than fluconazole (see Appendix 2) who are unable to switch their prophylaxis to fluconazole, or discontinue antifungal prophylaxis, for 7 days prior to first day of study drug administration.
  • Active cancer, other than AML, requiring systemic chemotherapy or biological therapy within 6 months of study entry. Patients who have received only hormonal therapy in the or adjuvant setting in the past 6 months may participate in this study.
  • Symptomatic congestive heart failure, unstable angina, or cardiac arrhythmia.
  • Other conditions that could jeopardize the subject's ability to comply with the protocol, including, but not limited to, dementia, psychosis, or other major psychiatric disorder
  • Pregnant or breast feeding
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment

    Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.

    Drug: KX2-391

Interventions

  • Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.

    Also known as: KX01

06

What researchers measure

Primary outcomes

  1. To determine the maximum tolerated dose of KX2-391 when given once-daily to AML patients.

    The MTD will be used to determine the recommended Phase 2 dose that is associated with an approximately 33% DLT rate during the first 28 days of treatment in elderly patients with AML

    Time frame: 28 days

Secondary outcomes

  1. Evaluate pharmacokinetics, pharmacodynamics and activity of KX2-391.

    The pharmacokinetics and pharmacodynamics of KX2-391 will be evaluated in AML patients by measuring serum and bone marrow levels of drug and evaluating the disruption of microtubule networks in these samples to determine whether target inhibition has occurred at the doses tested. Hematological and bone marrow response will be assessed according to International Working Group (IWG)-AML criteria.

    Time frame: 28 days

07

Study locations

3 sites
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
08

References and documents

Publications

  • Kasner MT, Halloran MB, Pan J, Ritchie EK, Fetterly GJ, Kramer D, Hangauer DG, Thompson JE. A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia. Invest New Drugs. 2022 Aug;40(4):773-781. doi: 10.1007/s10637-022-01255-1. Epub 2022 May 17. PubMed 35579731 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2011
First posted
Jul 20, 2011
Start
Dec 2013
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Dec 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01397799
Responsible party
Sponsor
First posted
Jul 20, 2011
Start date
Dec 2013
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Dec 7, 2015

Study contacts

James Thompson, MD
principal investigator · Roswell Park Cancer Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirbanibulin

Start the discussion